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years. Yet, 17.5% of these patients have some degree of 
renal impairment (defined as eGFR <60 ml/min/1.73 m 2 ) 
[Houssiau et al., unpubl. data]. Since most of these pa-
tients are currently below the age of 40, it is anticipated 
that a significant percentage of them will eventually de-
velop end-stage renal disease. Although we still partially 
ignore why some LN patients do not respond to therapy, 
the consensus is that an early response to induction im-
munosuppressive therapy has a high positive predictive 
value for a good long-term renal outcome  [2] . In this re-
spect, the fact that only a relatively small proportion of 
LN patients achieve complete renal remission at 6–12 
months stresses the need for additional or alternative ap-
proaches, of which biologics might play a pivotal role by 
improving early complete remission rates. A second rea-
son why biologics should be tested in LN stems from the 
side effects of current immunosuppressive regimens. One 
should keep in mind that most of the damage observed in 
systemic lupus erythematosus is related to the use of glu-
cocorticoids (GC)  [3, 4] . The possibility that biologics 
might display a major GC-sparing effect is not farfetched, 
as suggested by recent data obtained with an oral steroid-
free regime combining rituximab (RTX) and mycophe-
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 Abstract 
 This position paper critically analyzes the available con-
trolled data regarding biologic therapy in lupus nephritis 
(LN). Rather than an exhaustive review of all published evi-
dence, the stress is put on the unmet medical needs in LN, 
the design of trials aimed at testing the effect of a biologic in 
LN, the possible reasons for LN trial failures and the future of 
biological therapy in LN.  © 2014 S. Karger AG, Basel 
 Why Do We Need Biologics in Lupus Nephritis? 
 Lupus nephritis (LN) is a feared disease manifestation 
of systemic lupus erythematosus, affecting between 30 
and 60% of the patients  [1] , with a higher prevalence in 
childhood-onset cases. While most patients can be suc-
cessfully treated in the short term with current immuno-
suppressants, the long-term outcome is not so bright. 
Thus, in our own inception cohort of biopsy-proven LN 
(LOULUNIC; Louvain Lupus Nephritis Inception Co-
hort), we are pleased to claim that only 4% suffer from 
end-stage renal disease after a mean follow-up of 6.5 
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nolate mofetil (MMF) (RITUXILUP regime)  [5] . Thirdly, 
biologic therapy might be of interest to reduce the rate of 
renal flares, which are quite common despite mainte-
nance immunosuppression with low-dose GC, azathio-
prine or MMF, and have a deleterious impact on long-
term renal outcome, mainly in case of nephritic flares.
 How to Run a LN Trial Aimed at Testing a Biologic? 
 From a theoretical viewpoint, four different designs 
can be (have been) tested. First, biologics can be evalu-
ated as an ‘add-on’ induction therapy superimposed to 
the standard of care (SOC). In this setting, patients re-
ceive GC and another immunosuppressant [MMF or in-
travenous cyclophosphamide (CY)], and either placebo 
or the study drug. Unless the primary endpoint is set far 
enough from baseline (at least 1 year, ideally 2), much of 
the effect might be driven by SOC, mainly by GC, which 
may obscure the potential benefit of the study drug, in 
casu the biologic agent, except if the study drug is a won-
der drug. The other possible drawback is to cumulate ad-
verse events, some of which could be wrongly assigned to 
the study drug instead of SOC. In other words, in an add-
on approach, both efficacy and toxicity might well be 
driven by SOC. A second design is a modified draft of an 
add-on protocol in which the dose of GC is reduced to a 
minimum. The aim of this ‘low-dose/no GC’ approach, 
used in the RITUXILUP regime, is to avoid the afore-
mentioned pitfalls  [5] . While this might be game-chang-
ing, it should be stressed that it still needs to be tested in 
a controlled trial  [6] . A third possibility is to test biologics 
in patients who do not display a sufficient level of re-
sponse in terms of reduction of proteinuria after 3–6 
months of SOC, i.e. in patients suffering from refractory 
disease, or at least experiencing a suboptimal response to 
induction therapy. Actually, this is how RTX has been (is 
still) used by lupologists in clinical practice. Many se-
ries – again uncontrolled – indicate that RTX might be 
efficacious in this niche indication, as also suggested by 
registry data  [7–9] . The ATLAS (anti-TWEAK) and the 
RING (RTX) trials are testing this approach. One advan-
tage of this design is that the dose of GC is mostly re-
duced by the time the biologic is introduced, which may 
contribute to reduce toxicity and increase the chance of 
unmasking the effect of the study drug. Lastly, biologics 
could be tested as long-term maintenance therapy, as al-
ready alluded to. This design is, however, unlikely to be 
tested by pharma trials, as it requires a long observation 
period (at least 3 years).
 Why Have LN Trials Failed Thus Far? 
 Table  1 lists the randomized controlled LN trials in 
which a biologic agent has been tested and summarizes 
the major conclusions. So far, results have been reported 
for anti-CD20 RTX (LUNAR trial)  [10] , anti-CD20 ocrel-
izumab (OCR; BELONG trial)  [11] , CTLA4-Ig abatacept 
(ABA; BMS and ACCESS trials)  [12, 13] , anti-BLyS (B 
lymphocyte stimulator)/APRIL (A proliferation-induc-
ing ligand) receptor construct atacicept (ATA)  [14] , anti-
gen-presenting cell modulator laquinimod  [15] and anti-
IL6 sirukumab  [16] . None of these trials reached its pri-
mary endpoint. While the reasons for these failures are 
obviously speculative, three scenarios can be sketched.
 First, some drugs turned out to be more toxic than 
anticipated, at least in combination with the other im-
munosuppressants used in these trials. Thus the 
 BELONG trial was terminated early because of an imbal-
ance in serious infections in OCR-treated patients versus 
placebo-treated patients when the study drug was com-
bined with MMF [and not to Euro-Lupus (EL) intrave-
nous CY] given as background immunosuppressive 
therapy  [11] . Of note, many more MMF patients had re-
ceived  ≥ 1 g intravenous methylprednisolone compared 
to EL patients, suggesting that increased intravenous GC 
use might explain the increased infection rate observed 
in patients treated with the combination of OCR and 
MMF. Another example of premature termination for 
toxicity is the ATA LN trial, in which patients received 
placebo or ATA on a background of GC and MMF  [14] . 
The trial was interrupted after the enrollment of only 6 
patients (2 placebo and 4 ATA). Three out of the 4 ATA 
patients developed severe hypogammaglobulinemia (se-
rum IgG <3 g/l) and all three suffered from severe infec-
tion ( Haemophilus influenzae pneumonia,  Legionella 
pneumophila pneumonia and  Bacillus bacteremia ). In-
terestingly, the results of a nonrenal lupus ATA flare pre-
vention trial were recently released and the high-dose 
ATA group was also prematurely terminated because 2 
patients died of severe infection, despite normal serum 
IgG levels  [17] . It may be that combined blockade of 
BLyS and APRIL really explodes the infectious risk. Yet, 
experienced clinical lupologists are well aware that LN 
patients are extremely exposed to severe infection within 
the first weeks of therapy and that fatal cases are – alas – 
not so infrequent, even within the frame of convention-
al immunosuppressive treatment.
 Second, LN trials might have missed their primary 
endpoint because of poor design. Amongst others, the 
following criticisms can be raised: (1) wrong definition 
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of the primary outcome measure, (2) superiority design 
required by the medical agencies, (3) too much immu-
nosuppressive comedications (in particular too much 
GC), (4) statistical power defined on a too ambitious 
effect (the 11% benefit in favour of RTX in the LUNAR 
trial did not reach statistical significance, but was with-
in the range of the statistically significant effect of anti-
BLyS belimumab in two pivotal nonrenal lupus trials) 
 [18, 19] , (5) trial was too short and (6) underestimation 
of the role of ethnicity, etc. The pivotal importance of 
choosing the right outcome measure as the primary 
endpoint has been remarkably illustrated by the reanal-
ysis of the failed BMS ABA LN trial. The very low re-
sponse rates in each group using the original BMS pri-
mary outcome measure  [12] led to reanalysis of the data 
 [20] . Using other definitions of renal response, i.e. out-
come measures used as primary endpoints in other LN 
trials, statistically significant and even clinically relevant 
differences could be unmasked in favor of ABA. The 
obligation of a superiority design for regulatory purpos-
es is another major reason for ‘failure’. Since no immu-
nosuppressant is currently labelled for LN, a study drug 
must be shown to be superior to the controlled arm, 
which is clearly difficult when the comparator is intra-
venous CY combined to high-dose GC. Rather, a non-
inferiority design could also be appropriate and clini-
cally relevant if the trial indicates that the study drug is 
as good as the control arm but much less toxic. This 
design was chosen for the RITUXILUP trial, a soon-to-
be-running investigator-initiated study, with the hope 
to demonstrate that LN patients given MMF and RTX 
will perform as well as patients given MMF and high-
dose GC, with less adverse events. Such an approach 
could position biologics as safer drugs than SOC. That 
said, the ultimate goal in LN is to prevent renal impair-
ment and renal replacement therapy. Therefore, a new 
treatment – a fortiori more expensive – should also 
demonstrate additional efficacy and be validated by a 
pharmacoeconomic approach. In this respect, the cost 
of renal replacement therapy is so high that avoidance 
of only a few cases of end-stage renal disease might be 
cost-effective in a LN patient population.
 The third hypothesis is that some of our educated 
guesses regarding potential targets are wrong and that 
the pivotal pathogenic pathways operating in LN have yet 
to be unraveled. Thus, while the relevance of preclinical 
lupus models for human LN cannot be overlooked, ‘mice 
are not merely furry small humans with long tails’, as 
nicely written by William Stohl in a recent review  [21] . It 
is likely that pathogenic immune mechanisms are at 
work in LN patients well before the disease becomes clin-
ically detectable, a picture obviously different in murine 
systemic lupus erythematosus in which very early events 
can be captured, dissected and targeted. At later (i.e. clin-
ical) stages of the human disease, other molecular path-
ways may have taken the lead. In this respect, more at-
tention should be paid to the mechanisms leading from 
reversible immune-mediated inflammation to glomeru-
lar and interstitial fibrosis. How the immune system is 
reconstituted in LN patients after biologic therapy is yet 
another area of uncertainty, which may be of critical im-
portance for relapses and late outcome. For instance, it is 
known that serum BLyS levels increase after RTX treat-
ment  [22] , which might negatively impact the autoim-
mune repertoire, potentially facilitating renal relapses. 
The soon to be started CALIBRATE trial (Combination 
of Antibodies in Lupus Nephritis: Belimumab and Ritux-
imab Assessment of Tolerance and Efficacy) is therefore 
aimed at testing whether a low-BLyS environment would 
favour recovery of a nonautoreactive B cell compartment 
following RTX therapy. Last, but not least, relapses of LN 
are likely driven by long-lived plasma cells which are not 
targeted by current immunosuppressive and biologic 
agents. Proteasome inhibitors have been shown to be ef-
ficacious in preclinical models  [23] , but this approach 
raises toxicity issues, as autoimmune long-lived plasma 
cells are unlikely to be specifically targeted by agents like 
bortezomid.
 The Future Might Be Brighter 
 The preceding paragraphs may make the reader be-
lieve that biologics are shooting stars and that the picture 
is just too sophisticated to see light in the night of bio-
logic therapy in LN. However, the opposite is true, al-
though one should not expect to achieve efficacy in all LN 
cases with a single wonder drug, because LN is such a 
complex and pleiotropic disease (compared to rheuma-
toid arthritis)! There are many reasons for patients, clini-
cians, investigators and pharma companies to keep the 
faith. First, we have learned from our mistakes. ‘Old’ 
drugs, like RTX or ABA, are therefore still studied in LN, 
with more appropriate designs and outcome measures. 
Second, at least three LN trials are running: the anti-
TWEAK BIIB023 ATLAS trial, the new ABA BMS trial 
and the anti-BLyS Belimumab LN trial  [18, 19] . Other 
potential LN trials are under discussion, awaiting the re-
sults of the corresponding nonrenal trials with anti-CD22 
epratuzumab  [24] , blisibimod (fusion protein between Fc 
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portion of IgG and a synthetic peptide sequence that 
binds to BLyS; PEARL trial)  [25] , anti-BLyS tabalumab 
(ILLUMINATE trials)  [26] , anti-IFNα sifalimumab  [27] , 
anti-IFNα AGS-009  [28] , anti-IFNα rontalizumab  [29] , 
IFN kinoid  [30] , anti-IFNAR (type I IFN receptor) MEDI-
546  [31] or rigerimod, an immunomodulating autoanti-
genic peptide derived from U1-RNP  [32] . The third rea-
son for hope is that cooperation among lupologists is 
more efficient than ever, as demonstrated by the number 
of investigator-initiated studies in the field of LN, e.g. 
RITUXILUP, CALIBRATE, RING. Interestingly, these 
trials were endorsed by the recently launched Lupus Ne-
phritis Trials Network, whose aim is to improve out-
comes for LN patients through the conduct of clinical tri-
als designed to prevent chronic kidney disease and 
through the development of clinical trial methodologies 
that improve and simplify the assessment of therapeutic 
agents (http://lupusnephritis.org).
 Conclusion 
 While LN trials with biologics have failed so far to 
reach their primary endpoints, this does not imply that 
biologic therapy has no place in the bedside armamen-
tarium. Thus, none of us who have successfully treated 
several desperate LN cases with RTX would hesitate to try 
the drug in refractory cases, prior to giving up. Hopefully, 
many other studies, with several ‘first-in-class drugs’, will 
open new treatment avenues in this threatening disease. 
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